Drug Profile
HM 15410
Alternative Names: HM15410Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Iduronate sulfatases
- Mechanism of Action Iduronate sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mucopolysaccharidosis II
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-II in South Korea
- 25 Apr 2017 Preclinical trials in Mucopolysaccharidosis II in South Korea (unspecified route)